Abstract P5-09-21: Selective Androgen Receptor Modulators (SARMs): Enobosarm as Targeted Therapy for the Treatment of Androgen Receptor-Positive Breast Cancer
December 2013
in “
Cancer research
”
Studysummary In this study, GTx-027, a selective androgen receptor modulator, significantly inhibited tumor growth in certain breast cancer models and showed good tolerance in a Phase II trial with postmenopausal women. Our plain-language summary of this paper — not a Tressless recommendation.
The study investigated the use of selective androgen receptor modulators (SARMs), specifically enobosarm, as a targeted therapy for androgen receptor-positive breast cancer. In vitro and in vivo experiments demonstrated that SARMs, including enobosarm and GTx-027, significantly inhibited the proliferation and tumor growth of AR-expressing breast cancer cells without the virilizing side effects associated with non-tissue-selective androgens. Phase II clinical studies in postmenopausal women showed that enobosarm was well tolerated and led to significant improvements in lean body mass and physical function without affecting sebaceous gland volume, hair growth, endometrial thickness, or causing bleeding. These findings suggested that SARMs could offer a novel and effective treatment option for AR-positive breast cancer.
